Nubeqa® (darolutamide)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Key Facts
About Bayer
Bayer AG's mission is 'Health for all, Hunger for none,' focusing on advancing healthcare and food security through science-led innovation. The company has achieved significant scale and diversification, most notably through the transformative acquisition of Monsanto, establishing a leading position in agricultural sciences. Its strategy centers on driving growth in its core pharmaceutical pipeline—particularly in oncology, cardiology, and cell & gene therapy—while navigating legacy legal challenges and optimizing its portfolio to enhance shareholder value and operational focus.
View full company profileAbout Bayer
Bayer AG's mission is 'Health for all, Hunger for none,' focusing on advancing healthcare and food security through science-led innovation. The company has achieved significant scale and diversification, most notably through the transformative acquisition of Monsanto, establishing a leading position in agricultural sciences. Its strategy centers on driving growth in its core pharmaceutical pipeline—particularly in oncology, cardiology, and cell & gene therapy—while navigating legacy legal challenges and optimizing its portfolio to enhance shareholder value and operational focus.
View full company profileTherapeutic Areas
Other Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Decipher Prostate | Decipher Biosciences | Launch |
| CHAI Biomarker | Valar Labs | Development/Validation |